Novel antidepressant drugs, arterial hypertension and cardiovascular disease

Recent Patents on Cardiovascular Drug Discovery

Volumn 8, Issue 3, 2013, Pages 178-185

  Katsi, Vasiliki K ^a   Marketou, Maria ^b   Vamvakou, Georgia ^c   Makris, Thomas ^d   Tousoulis, Dimitris ^e   Stefanadis, Christodoulos I ^e   Vardas, Panos ^b   Kallikazaros, Ioannis E ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d General District Hospital Helena Venizelou   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Arterial hypertension; Bupropion; Cardiovascular disease; Depression; Fluoxetine; Norepinephrine reuptake inhibitors; Serotonin reuptake inhibitors

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE;

ACUTE HEART INFARCTION; ARTICLE; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MALFORMATION; CARDIOVASCULAR SYSTEM; DEPRESSION; ELEVATED BLOOD PRESSURE; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; ORTHOSTATIC HYPOTENSION; PATENT; PRIORITY JOURNAL; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; PATHOPHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BUPROPION; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOHEXANOLS; HUMANS; HYPERTENSION; PATENTS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84900831260     PISSN: 15748901     EISSN: 22123962     Source Type: Journal    
DOI: 10.2174/1574890109666140407154738     Document Type: Article

References (83)

1. Pierre JM. Mental illness and mental health: is the glass half empty or half full? Can J Psychiatry. 2012; 57:651-8.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nature Med 1998; 4:1241-1243.
3. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a metaanalysis. Psychosom Med 2004; 66:802-813.
4. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27:2763-2774.
5. Azevedo A, Bettencourt P, Frioes F, Alvelos M, Abreu-Lima C, Hense HW, et al. Depressive Symptoms and Heart Failure Stages. Psychosomatics 2008;49:42-48.
6. Singh, P., Pirio, M.R. Imipramine derivatives and poly (amino acid) conjugates. US4275160 (1981).
7. Ables AZ, Baughman OL. Antidepressants: update on new agents and indications. Clinical pharmacology 2003;67:547-554.
8. Januzzi JL, Stern TA, Pasternak RC, DeSanctis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med. 2000;160: 1913-21.
9. Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf.2012;4:93-101.
10. Stark, P. Use of fluoxetine for the manufacture of an anti-anxiety agent. EP0123469 B1 (1987).
11. Craig, A.S., Jones, D.A., O'Keeffe, D., Ward, N. Paroxetine. WO2001012624 (2001)
12. Holm, P., Lijegren, K. Pharmaceutical composition containing citalopram. WO2002053133A1 (2002).
13. Svensson, H.T. Use of escitalopram for improving cognition. EP2026793A2 (2009).
14. Remenar, J., MacPhee, M., Peterson, M.L., Tawa, M. Sertraline compositions. US7186863 B2 (2007).
15. Valducci, R., Alighieri, T., Avanessian, S. Controlled release pharmaceutical composition of venlafaxine hydrochloride, and process for preparation thereof. WO2007039569 (2006).
16. Tung, R. Antidepressant compounds. WO2010028130 (2010).
17. Buchwald, S., Swager, T., Rariy, R. Methods for the synthesis of milnacipran and congeners thereof. WO2005118564 (2005).
18. Sesha, R. Antidepressant oral pharmaceutical compositions. US8513439 B2 (2013).
19. Airoldi, A., Martini, A., Zampieri, M. Pharmaceutical salts of reboxetine. EP1515959 B1 (2009).
20. Skrabanja, A.T.P., Tully, R.E. Oral liquid solution comprising the antidepressant mirtazapine. EP 1067934 B1 (2003).
21. Jackson, R.W., Subasinghe, K.R. Resolution of optically-active compounds. EP1017695A1 (2000).
22. Luke, G. M., Mayol, R.F. Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones andtriazoldiones.US5256664A(1993). http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=5256664A&KC=A&FT=D
23. Schatzberg AF. New indications for antidepressants. J Clin Psychiatry 2000; 61: 9-17.
24. Joseph J, Keene JR, Galt T, Martin F. Antidepressants use in psychiatry and medicine. J Am Dent Assoc. 2003;134: 71-9.
25. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum Psychopharmacol. 2013; 28: 151-9.
26. Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. American Heart Association Statistics Committee of the Council on Epidemiology and Prevention and the Council on Cardiovascular and Stroke Nursing. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014; 129:1350-69.
27. Miyazaki M, Roose SP. Pharmacologic treatment of depression in patients with heart disease. Psychosom Med 2005;67:54-57.
28. Cohen H, Kotler M, Matar M, Kaplan Z. Normalization of Heart Rate Variability in Post-Traumatic Stress Disorder Patients Following Fluoxetine Treatment: Preliminary Results. Isr Med Assoc J. 2000;2:296-301.
29. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des. 2004; 10: 2463-75.
30. Kobayashi T, Washiyama K, Ikeda K. Inhibition of G proteinactivated inwardly rectifying K+channels by different classes of antidepressants. Plos One 2011; 6:e28208.
31. Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, et al. The G-protein-gated atrial K+channel IKACh is a heteromultimer of two inwardly rectifying K+-channel proteins. Nature 1995; 374:135-141.
32. Diamond M, Kelly JP, Connor TJ. Antidepressants suppress production of the Th1 cytokine interferon-γ, independent of monoamine transporter blockade. Eur Neurophsycopharmacol 2006;16:481-90.
33. Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, Kremastinos DT. Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules. Int J Cardiol. 2010; 139:150-158
34. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial in farction: findings from a double-blind, placebo-controlled trial. Phychosom Med 2000; 62:783-789.
35. Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.CMAJ 2011;183:1835-1843.
36. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 2008;64:275-282.
37. Sarretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Phychiatry 2010; 71:1259-1272.
38. Beyazyüz M, Albayrak Y, Eǧilmez OB, Albayrak N, Beyazyüz E. Relationship between SSRIs and Metabolic Syndrome Abnormalities in Patients with Generalized Anxiety Disorder: A Prospective Study. Psychiatry Investig.2013;10:148-154.
39. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry.2013; 74: 293-308.
40. Viswaprasad, V., Haranatha, B.B., Hidaytulla, S., Aga, K., Dattatray, D., Umesh, N.K., et al. Stable dosage forms of an antidepressant. WO2007060540A1 (2007).
41. Harris J, Heil JS. Managing depression in patients with advanced heart failure awaiting transplantation. Am J Health Syst Pharm 2013; 70: 867-873.
42. Arias HR, Santamaría A, Ali SF. Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol 2009;88: 223-255.
43. Clayton AH. Antidepressant-Associated Sexual dysfunction: A Potentially Avoidable Therapeutic Challenge. Primary Psychiatry 2003; 10: 55-61.
44. Dhillon, S., Yang, LP, Curran M.P. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68: 653-689.
45. Riggotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. AM J Med 2006 Dec;119: 1080-1087.
46. Paganelli MO, Martins LC., Chaud, M.V., Ferreira-Melo, S.E., Sabha, M., do Prado, J.F., et al. Hemodynamic effects of a combination of bupropion and nicotine in anesthetized dogs. Cardiovasc Toxicol 2006; 6: 63-68.
47. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Phychiatry 2005; 66: 253-259.
48. Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Phychiatry 1991; 148: 512-516.
49. Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003; 37: 999-1002.
50. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999; 21:454-63.
51. Martins C, Ferreira-Melo SE, Sabha M, Coelho O, Yugar-Toledo JC, Quinaglia T, et al. Acute effects of pharmacotherapies in blood pressure in normotensive moderate smokers. Blood Press 2009; 18:255-260.
52. Planer D, Lev I, Elitzur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. Arch Intern Med 2011;171:1055-1060.
53. Thase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, et al. A randomized, double-blind, placebo-controlled study of the effects of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol 2008; 28:302-307.
54. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008;118:434-442.
55. Hojer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila) 2008;46: 336-337.
56. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007;64:192-197.
57. Isbister GK. Electrocardiogram changes and arrhythmias in venlafaxine overdose. Br J Clin Pharmacol. 2009;67:572-576.
58. Batista M, Dugernier T, Simon M, Haufroid V, Capron A, Fonseca S, et al. The spectrum of acute heart failure after venlafaxine overdose. Clin Toxicol (Phila). 2013;51:92-95.
59. Neil CJ, Chong CR, Nguyen TH, Horowitz JD. Occurrence of Tako-Tsubo cardiomyopathy in association with ingestion of serotonin/ noradrenaline reuptake inhibitors. Heart Lung Circ. 2012;21: 203-205.
60. Periclou A, Palmer RH, Zheng H, Lindamood C. 3rd. Effects of milnacipran on cardiac repolarization in healthy participants. J Clin Pharmacol. 2010; 50: 422-433.
61. Forman MB, Sutej PG, Jackson EK. Hypertension, tachycardia, and reversible cardiomyopathy temporally associated with milnacipran use. Tex Heart Inst J. 2011; 38: 714-718.
62. Parikh AR, Thatcher BT, Tamano EA, Liskow BI. Suicidal ideation associated with duloxetine use: a case series. J Clin Psychopharmacol 2008; 28:101-102.
63. Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30:437-455.
64. Archer DF, Pinkerton JV, Guico-Pabia CJ, Hwang E, Cheng RF. Study 3353 Investigators. Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Menopause 2013;20: 47-56.
65. Van MJP, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns H J, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007;190: 460-466.
66. de Jonge, P., Honig, A., van, M. J. P., Schene, A. H., Kuyper, A. M., Tulner, D., et al. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry 2007; 164:1371-1378.
67. Koseoglu Z, Kara B, Satar S. Bradycardia and hypotension in mianserin intoxication. Hum Exp Toxicol. 2010;29: 887-888.
68. Paslakis G, Gilles M, Lederbogen F, Schilling C, Scharnholz B, Deuschle M. The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. Eur Arch Psychiatry Clin Neurosci. 2011; 261:173-177.
69. Mayer A. F., Schroeder, C., Heusser, K., Tank, J., Diedrich, A., Schmieder RE, et al. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension 2006; 48:120-126.
70. Delalleau, B. Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients. EP2295050 A1 (2011).
71. Munoz C. Valdoxan: a novel treatment for depressive episodes with a distinctive profile of antidepressant efficacy. Medicographia 2011;33:180-186.
72. Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9:628-642.
73. Munoz C. Better quality remission in depression: Valdoxan, the first melatonergic antidepressant, Medicographia. 2009;31:175-181.
74. Dubovsky SL, Warren C. Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs. 2009; 18:1533-1540.
75. Whooley MA. Depression and Cardiovascular Disease: Healing the Broken-Hearted. JAMA. 2006; 295: 2874-2881.
76. Fatemi SH, Emamian ES, Kist DA. Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression. Ann Pharmacother 1999; 33:701-703.
77. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7:139-147.
78. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation inmajor depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166: 980-991.
79. Wójciak P, Remlinger-Molenda A, Rybakowski J. The role of oxytocin and vasopressin in central nervous system activity and mental disorders Psychiatr Pol.2012; 46: 1043-1052.
80. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10-21.
81. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010; 24:479-499.
82. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012; 28: 1717-17124.
83. Chen G, Lee R, Højer AM, Buchbjerg, JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant Clin Drug Investig. 2013; 33: 727-736.